Novartis UK has announced that the MHRA has given a positive scientific opinion for the investigational treatment, asciminib

Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEO fkansteiner Mon, 01/24/2022 – […]

Bayer leads $80M funding round for Cellino, betting on new cell therapy manufacturing platform kdunleavy Tue, 01/25/2022 – […]

Roche’s aim to widen Evrysdi’s label nabs speedy FDA review in young spinal muscular atrophy patients fkansteiner Tue, […]

Samsung Biologics outlines mRNA ambitions as “Super Plant” speeds toward completion fkansteiner Tue, 01/25/2022 – 10:56

Deciphera details stomach cancer flop against Pfizer’s Sutent, cracking the door open for off-label use aliu Tue, 01/25/2022 […]

There may be more to the situation than can be shared with youNicola Brown, human resources and employment […]

In their trial of a programme to prevent falls in older people, Logan and colleagues show that training […]

A moderate amount of a peptide-enhanced cancer drug goes a long way in treating breast cancers that metastasize […]

At the time of writing (24 January 2022), unvaccinated NHS workers in England have only until 3 February […]